Moderna and Merck announced successful Phase 3 trial results for their personalized mRNA melanoma vaccine combined with Keytruda, showing significant improvement in recurrence-free and distant metastasis-free survival. This marks the first positive late-stage trial for an individualized mRNA cancer vaccine, boosting Moderna's shares by over 160% intraday to around $163. Despite the surge, analyst price targets remain below the new trading price, with focus now shifting to full data release, regulatory review, and commercial launch plans.
Tempus AI agreed to acquire Personalis for $1.5 billion in a stock deal, gaining access to Personalis's ultrasensitive cancer DNA detection test, NeXT Personal. This technology supports a personalized mRNA cancer vaccine by Moderna and Merck, which r...
Moderna's stock surged over 125% in one week, driven by positive interim results from its Phase 3 trial of a personalized mRNA cancer vaccine for high-risk melanoma patients. The trial, conducted with partner Merck, showed success without new safety ...
Moderna's stock jumped 93% following the announcement that its Phase 3 melanoma trial, conducted with Merck, met its primary endpoint by significantly improving recurrence-free survival when combined with Merck's Keytruda. This marks the first positi...
Moderna and Merck reported positive Phase 3 trial results for their personalized mRNA-based cancer vaccine combined with Keytruda, showing significant improvement in recurrence-free survival for melanoma patients. This marks the first successful Phas...
Merck and Moderna announced positive initial results from their first late-stage trial of an experimental personalized cancer vaccine combined with Merck's immunotherapy Keytruda. The phase three trial involving over 1,100 melanoma patients showed th...
